抄録

We examined the association between serum concentrations of β-alanine, a metabolite of carnosine and anserine, and the risk of dementia in a general population of elderly Japanese persons. In 2007, 1,475 residents of Hisayama, Japan, aged 60-79 years and without dementia were divided into 4 groups according to quartiles of serum β-alanine concentrations (quartile 1, lowest; quartile 4, highest) and followed for a median of 5.3 years. During follow-up, 117 subjects developed all-cause dementia (Alzheimer in 77 cases and vascular dementia in 31). The risk of all-cause dementia decreased with increasing serum β-alanine levels after adjustment for potential confounding factors (quartile 2, hazard ratio (HR) = 0.73 (95% confidence interval (CI): 0.45, 1.18); quartile 3, HR = 0.50 (95% CI: 0.28, 0.89); quartile 4, HR = 0.50 (95% CI: 0.27, 0.92); P = 0.01 for trend). A similar inverse association was observed for Alzheimer disease (quartile 2, HR = 0.78 (95% CI: 0.44, 1.38); quartile 3, HR = 0.53 (95% CI: 0.26, 1.06); quartile 4, HR = 0.53 (95% CI: 0.25, 1.10); P = 0.04 for trend) but not for vascular dementia. We found that higher serum β-alanine levels were significantly associated with lower risks of all-cause dementia and Alzheimer disease. Because serum β-alanine levels reflect intakes of carnosine/anserine, higher intakes of carnosine/anserine might be beneficial for the prevention of dementia.

元の言語英語
ページ(範囲)1637-1645
ページ数9
ジャーナルAmerican journal of epidemiology
188
発行部数9
DOI
出版物ステータス出版済み - 9 1 2019

Fingerprint

Alanine
Dementia
Anserine
Carnosine
Confidence Intervals
Serum
Vascular Dementia
Alzheimer Disease
Japan
Population

All Science Journal Classification (ASJC) codes

  • Epidemiology

これを引用

@article{b9258b774bfc4e11bbbfd4fc2efd0532,
title = "Association between Serum β-Alanine and Risk of Dementia",
abstract = "We examined the association between serum concentrations of β-alanine, a metabolite of carnosine and anserine, and the risk of dementia in a general population of elderly Japanese persons. In 2007, 1,475 residents of Hisayama, Japan, aged 60-79 years and without dementia were divided into 4 groups according to quartiles of serum β-alanine concentrations (quartile 1, lowest; quartile 4, highest) and followed for a median of 5.3 years. During follow-up, 117 subjects developed all-cause dementia (Alzheimer in 77 cases and vascular dementia in 31). The risk of all-cause dementia decreased with increasing serum β-alanine levels after adjustment for potential confounding factors (quartile 2, hazard ratio (HR) = 0.73 (95{\%} confidence interval (CI): 0.45, 1.18); quartile 3, HR = 0.50 (95{\%} CI: 0.28, 0.89); quartile 4, HR = 0.50 (95{\%} CI: 0.27, 0.92); P = 0.01 for trend). A similar inverse association was observed for Alzheimer disease (quartile 2, HR = 0.78 (95{\%} CI: 0.44, 1.38); quartile 3, HR = 0.53 (95{\%} CI: 0.26, 1.06); quartile 4, HR = 0.53 (95{\%} CI: 0.25, 1.10); P = 0.04 for trend) but not for vascular dementia. We found that higher serum β-alanine levels were significantly associated with lower risks of all-cause dementia and Alzheimer disease. Because serum β-alanine levels reflect intakes of carnosine/anserine, higher intakes of carnosine/anserine might be beneficial for the prevention of dementia.",
author = "Jun Hata and Tomoyuki Ohara and Yoshinori Katakura and Kuniyoshi Shimizu and Shuntaro Yamashita and Daigo Yoshida and Takanori Honda and Yoichiro Hirakawa and Mao Shibata and Satoko Sakata and Takanari Kitazono and Satoru Kuhara and Toshiharu Ninomiya",
year = "2019",
month = "9",
day = "1",
doi = "10.1093/aje/kwz116",
language = "English",
volume = "188",
pages = "1637--1645",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Association between Serum β-Alanine and Risk of Dementia

AU - Hata, Jun

AU - Ohara, Tomoyuki

AU - Katakura, Yoshinori

AU - Shimizu, Kuniyoshi

AU - Yamashita, Shuntaro

AU - Yoshida, Daigo

AU - Honda, Takanori

AU - Hirakawa, Yoichiro

AU - Shibata, Mao

AU - Sakata, Satoko

AU - Kitazono, Takanari

AU - Kuhara, Satoru

AU - Ninomiya, Toshiharu

PY - 2019/9/1

Y1 - 2019/9/1

N2 - We examined the association between serum concentrations of β-alanine, a metabolite of carnosine and anserine, and the risk of dementia in a general population of elderly Japanese persons. In 2007, 1,475 residents of Hisayama, Japan, aged 60-79 years and without dementia were divided into 4 groups according to quartiles of serum β-alanine concentrations (quartile 1, lowest; quartile 4, highest) and followed for a median of 5.3 years. During follow-up, 117 subjects developed all-cause dementia (Alzheimer in 77 cases and vascular dementia in 31). The risk of all-cause dementia decreased with increasing serum β-alanine levels after adjustment for potential confounding factors (quartile 2, hazard ratio (HR) = 0.73 (95% confidence interval (CI): 0.45, 1.18); quartile 3, HR = 0.50 (95% CI: 0.28, 0.89); quartile 4, HR = 0.50 (95% CI: 0.27, 0.92); P = 0.01 for trend). A similar inverse association was observed for Alzheimer disease (quartile 2, HR = 0.78 (95% CI: 0.44, 1.38); quartile 3, HR = 0.53 (95% CI: 0.26, 1.06); quartile 4, HR = 0.53 (95% CI: 0.25, 1.10); P = 0.04 for trend) but not for vascular dementia. We found that higher serum β-alanine levels were significantly associated with lower risks of all-cause dementia and Alzheimer disease. Because serum β-alanine levels reflect intakes of carnosine/anserine, higher intakes of carnosine/anserine might be beneficial for the prevention of dementia.

AB - We examined the association between serum concentrations of β-alanine, a metabolite of carnosine and anserine, and the risk of dementia in a general population of elderly Japanese persons. In 2007, 1,475 residents of Hisayama, Japan, aged 60-79 years and without dementia were divided into 4 groups according to quartiles of serum β-alanine concentrations (quartile 1, lowest; quartile 4, highest) and followed for a median of 5.3 years. During follow-up, 117 subjects developed all-cause dementia (Alzheimer in 77 cases and vascular dementia in 31). The risk of all-cause dementia decreased with increasing serum β-alanine levels after adjustment for potential confounding factors (quartile 2, hazard ratio (HR) = 0.73 (95% confidence interval (CI): 0.45, 1.18); quartile 3, HR = 0.50 (95% CI: 0.28, 0.89); quartile 4, HR = 0.50 (95% CI: 0.27, 0.92); P = 0.01 for trend). A similar inverse association was observed for Alzheimer disease (quartile 2, HR = 0.78 (95% CI: 0.44, 1.38); quartile 3, HR = 0.53 (95% CI: 0.26, 1.06); quartile 4, HR = 0.53 (95% CI: 0.25, 1.10); P = 0.04 for trend) but not for vascular dementia. We found that higher serum β-alanine levels were significantly associated with lower risks of all-cause dementia and Alzheimer disease. Because serum β-alanine levels reflect intakes of carnosine/anserine, higher intakes of carnosine/anserine might be beneficial for the prevention of dementia.

UR - http://www.scopus.com/inward/record.url?scp=85072057664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072057664&partnerID=8YFLogxK

U2 - 10.1093/aje/kwz116

DO - 10.1093/aje/kwz116

M3 - Article

C2 - 31127276

AN - SCOPUS:85072057664

VL - 188

SP - 1637

EP - 1645

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 9

ER -